Exploration of the Risk of Suicidality and Self-Harm With GLP-1 Receptor Agonists: A Critical Appraisal

Exploration of the Risk of Suicidality and Self-Harm With GLP-1 Receptor Agonists: A Critical Appraisal

Exploration of the Risk of Suicidality and Self-Harm With GLP-1 Receptor Agonists: A Critical Appraisal

HC0087

Overview

Background
  • Safety concerns about the use of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have recently been raised, including a potential increased risk of self-harm and suicidal ideation.
Objectives
  • The aim of this project is to conduct a critical appraisal of the available real-world evidence to evaluate the association between GLP-1 RAs and the risk of suicidality and self-harm among patients with type 2 diabetes or obesity.

Manuscripts

Presentations

Project Team

Project Co-Lead
Samy Suissa PhD
Project Co-Lead
Laurent Azoulay PhD
Collaborator
Audray St-Jean MSc
Coordinating Center
Collaborator
Carolina Moriello MSc
Coordinating Center
Collaborator
Samantha Shapiro
Coordinating Center